Lecanemab Favors Early Aggregates. Fluorescently labeled lecanemab (green) bound most strongly to soluble Aβ aggregates ...

One of the major components of these protein buildups was thought to be a protein called amyloid beta, or Aβ42, which clump together into what is known as amyloid plaques. However, a new study ...

Researchers determine the differential risk of dementia among men and women based on the presence of obstructive sleep apnea.

However, while the level of Aβ42 in blood is not by itself a good biomarker for AD, the Aβ42:Aβ40 ratio has gained attention as a plasma biomarker that predicts amyloid-PET status regardless of ...

NICE has said it expects to evaluate dozens of potential treatments for Alzheimer’s disease over the next few years. Elisabeth Mahase examines what we know about these drugs This year the National ...

On Tuesday, Coya Therapeutics, Inc. (NASDAQ:COYA) released results from the placebo-controlled Phase 2 trial of LD IL-2 in ...

Chardan Capital analyst Keay Nakae reiterated a Buy rating on Coya Therapeutics, Inc. (COYA – Research Report) today and set a price ...

A groundbreaking research conducted in France has unveiled compelling evidence linking caffeine consumption to reduced ...

Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), has introduced LucentAD Complete, a new multi-marker ...

Coya (COY) stock tumbled 23% Tuesday on mixed results from a Phase 2 clinical trial of its therapy candidate LD IL-2 in the ...

Another Trump term could spur Europe’s efforts to stand on its own, but it is far from clear its leaders will seize the moment this time. By Steven Erlanger Beijing is expecting more ...